Connect with us

News

Anticoagulants Market by Route of Administration to grow by USD 18,091.94 million from 2023 to 2027; The increase in hip and knee surgeries is driving the market growth

Published

on

NEW YORK, May 31, 2023 /PRNewswire/ — The anticoagulants market size is forecast to increase by USD 18,091.94 million from 2023 to 2027, at a CAGR of 8.42%, according to the recent market study by Technavio. The growth of the market will be driven by the Introduction of novel oral anticoagulants, Growing prevalence of coagulation disorders, and Increase in hip and knee surgeries.

Key Benefits for Industry Players & Stakeholders – 

  • The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
  • It also provides detailed analyses of the market’s competitive landscape and vendors’ product offerings.
  • The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Technavio categorizes the global anticoagulants market Vendor Analysis:

Technavio has extensively analyzed 15 major vendors, including Abbott Laboratories, Amphastar Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Novartis AG, Pfizer Inc., Sanofi SA, Shenzhen Hepalink Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and United Therapeutics Corp.

Vendor Offerings –

  • Abbott Laboratories – The company offers anticoagulants such as ACITROM which functions as a vitamin K antagonist.
  • Aspen Pharmacare Holdings Ltd – The company offers anticoagulants such as THROMBOSIS.
  • AstraZeneca PLC – The company offers anticoagulants under the brand Alexion pharmaceuticals.

Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download The Sample Report

Expand operations in the future – To get requisite details, ask for a custom report.

Customer Landscape – Analysis of Price Sensitivity, Adoption Lifecycle, Customer Purchase Basket, Adoption Rates, and Purchase Criteria by Technavio

  • One of the core components of the customer landscape is price sensitivity, an analysis of which will help companies refine marketing strategies to gain a competitive advantage. 
  • Another key aspect is price sensitivity drivers (purchases are undifferentiated, the purchase is a key cost to buyers, and quality is not important), which range between LOW and HIGH.
  • Furthermore, market adoption rates for all regions have been covered.

Get a holistic overview of the endoscopic closure devices market by industry experts to evaluate and develop growth strategies. Download the Sample

Market Segmentation:

The anticoagulants market report extensively covers market segmentation by route of administration (oral anticoagulants and injectable anticoagulants), type (Factor Xa inhibitors, DTIs, Heparin, and Vitamin K antagonists), and geography (North America, Europe, Asia, and Rest of World (ROW)). 

The market share growth of oral anticoagulants segment which was valued at USD 19,827.74 million in 2017, will be significant during the forecast period. Oral anticoagulants can be categorized into two types, conventional oral anticoagulants, and NOACs. Conventional oral anticoagulants such as warfarin (COUMADIN) and generic warfarin have been on the market for 50 years. NOACs are indicated for DVT and non-valvular atrial fibrillation. These drugs have shown better results in terms of safety and efficacy when compared to traditional ones.

North America is estimated to contribute 51% to the growth of the global market during the forecast period. The anticoagulants market in North America has experienced significant growth in recent years due to the increasing prevalence of DVT and pulmonary embolisms in the region. Advanced healthcare system and increasing awareness of the severity of the disease are the primary factors driving the growth of the anticoagulants market in North America. Also, increasing governmnet support in the form of patient assistance programs contributs extensively to the market growth in this region.

Market Dynamics:

Market Driver:

The increase in hip and knee surgeries is notably driving the global anticoagulants market growth. Hip and knee replacement surgeries are frequently observed in the elderly population. It is reported that more than 1 million Americans undergo joint replacement surgeries each year. People who have had knee and hip replacement surgery are more likely to develop DVT. Among tjhe aged population, the cases of joint replacements and cardiovascular procedures are commonly observed health concerns. Hence, the increasing number of surgical procedures will increase the chances of developing thromboembolic events after surgeries. This requires treatment using anticoagulants. Therefore, the increase in hip and knee surgeries is expected to drive the growth of the global anticoagulants market during the forecast period.

Major Trends:

Increasing focus on emerging economies is the primary trend in the global anticoagulants market. Vendors are increasingly turning their attention to untapped markets such as the Middle East, Africa, India, and China due to significant growth in the healthcare sector. Additionally, the regulatory environment in many emerging markets is becoming more favorable for pharmaceutical companies, resulting in easier market entry and a faster approval process for new drugs. Such government supports in the pharmaceutical industry has made it easier for anticoagulant vendors to introduce new drugs and expand their sales volume. Thus, the increasing focus toward emerging economies will drive the growth of the global anticoagulants market during the forecast period.

Key Challenges:

Strong side effects of anticoagulants is a major challengein the global anticoagulants market. Long-term use of anticoagulants can lead to increased cardiovascular risks such as stroke and heart attack. Other side effects of anticoagulants are severe bruising, persistent nosebleeds, and vomiting. The regular or heavy usage of anticoagulants may lead to severe back pain, chest pain, dizziness, headaches, and jaundice. Due to such evident side effects the anticoagulant, the market is witnessing decline in its demand. Hence, increasing awareness on the side effects of anticoagulants is expected to hinder the growth of the global anticoagulants market during the forecast period.

To get detailed insights about inclusions and exclusions, buy the report 

Gain instant access to 17,000+ market research reports. 
Technavio’s SUBSCRIPTION platform

What are the key data covered in this Anticoagulants Market report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the anticoagulants market between 2023 and 2027
  • Precise estimation of the size of the anticoagulants market size and its contribution to the market in focus on the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the Anticoagulants Market industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of Anticoagulants Market vendors

Related Reports: 

The thrombosis drugs market share is expected to increase by USD 16.24 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 9.67%. This report extensively covers thrombosis drugs market segmentation by indication (pulmonary embolism and DVT) and geography (North America, Europe, Asia, and Rest of World (ROW)). Sedentary lifestyle is one of the key thrombosis drugs market trends that is expected to impact the industry positively in the forecast period.

The anticoagulant reversal drugs market share is expected to increase by USD 877.37 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 12.27%. This report extensively covers anticoagulant reversal drugs market segmentation by distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy) and geography (North America, Europe, Asia, and Rest of World (ROW)). Recent developments is one of the key anticoagulant reversal drugs market trends that is expected to impact the industry positively in the forecast period.

Anticoagulants Market Scope

Report Coverage

Details

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 8.42%

Market growth 2023-2027

USD 18,091.94 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

7.44

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 51%

Key countries

US, Canada, Germany, UK, and Japan

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, Amphastar Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Novartis AG, Pfizer Inc., Sanofi SA, Shenzhen Hepalink Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and United Therapeutics Corp.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents

1 Executive Summary

  • 1.1 Market overview 
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem 
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition 
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 13: Market segments
  • 3.4 Market outlook: Forecast for 2022-2027
    • Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
    • Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
    • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
    • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global anticoagulants market 2017 – 2021
    • Exhibit 18: Historic Market Size – Data Table on global anticoagulants market 2017 – 2021 ($ million)
  • 4.2 Route of Administration Segment Analysis 2017 – 2021
    • Exhibit 19: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
  • 4.3 Type Segment Analysis 2017 – 2021 
    • Exhibit 20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 – 2021
    • Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 – 2021
    • Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary 
    • Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers 
    • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers 
    • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants 
    • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes 
    • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry 
    • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
  • 5.7 Market condition 
    • Exhibit 29: Chart on Market condition – Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

  • 6.1 Market segments 
    • Exhibit 30: Chart on Route of Administration – Market share 2022-2027 (%)
    • Exhibit 31: Data Table on Route of Administration – Market share 2022-2027 (%)
  • 6.2 Comparison by Route of Administration 
    • Exhibit 32: Chart on Comparison by Route of Administration
    • Exhibit 33: Data Table on Comparison by Route of Administration
  • 6.3 Oral anticoagulants – Market size and forecast 2022-2027 
    • Exhibit 34: Chart on Oral anticoagulants – Market size and forecast 2022-2027 ($ million)
    • Exhibit 35: Data Table on Oral anticoagulants – Market size and forecast 2022-2027 ($ million)
    • Exhibit 36: Chart on Oral anticoagulants – Year-over-year growth 2022-2027 (%)
    • Exhibit 37: Data Table on Oral anticoagulants – Year-over-year growth 2022-2027 (%)
  • 6.4 Injectable anticoagulants – Market size and forecast 2022-2027 
    • Exhibit 38: Chart on Injectable anticoagulants – Market size and forecast 2022-2027 ($ million)
    • Exhibit 39: Data Table on Injectable anticoagulants – Market size and forecast 2022-2027 ($ million)
    • Exhibit 40: Chart on Injectable anticoagulants – Year-over-year growth 2022-2027 (%)
    • Exhibit 41: Data Table on Injectable anticoagulants – Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Route of Administration 
    • Exhibit 42: Market opportunity by Route of Administration ($ million)
    • Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Type

  • 7.1 Market segments 
    • Exhibit 44: Chart on Type – Market share 2022-2027 (%)
    • Exhibit 45: Data Table on Type – Market share 2022-2027 (%)
  • 7.2 Comparison by Type 
    • Exhibit 46: Chart on Comparison by Type
    • Exhibit 47: Data Table on Comparison by Type
  • 7.3 Factor Xa inhibitors – Market size and forecast 2022-2027 
    • Exhibit 48: Chart on Factor Xa inhibitors – Market size and forecast 2022-2027 ($ million)
    • Exhibit 49: Data Table on Factor Xa inhibitors – Market size and forecast 2022-2027 ($ million)
    • Exhibit 50: Chart on Factor Xa inhibitors – Year-over-year growth 2022-2027 (%)
    • Exhibit 51: Data Table on Factor Xa inhibitors – Year-over-year growth 2022-2027 (%)
  • 7.4 DTIs – Market size and forecast 2022-2027
    • Exhibit 52: Chart on DTIs – Market size and forecast 2022-2027 ($ million)
    • Exhibit 53: Data Table on DTIs – Market size and forecast 2022-2027 ($ million)
    • Exhibit 54: Chart on DTIs – Year-over-year growth 2022-2027 (%)
    • Exhibit 55: Data Table on DTIs – Year-over-year growth 2022-2027 (%)
  • 7.5 Heparin – Market size and forecast 2022-2027
    • Exhibit 56: Chart on Heparin – Market size and forecast 2022-2027 ($ million)
    • Exhibit 57: Data Table on Heparin – Market size and forecast 2022-2027 ($ million)
    • Exhibit 58: Chart on Heparin – Year-over-year growth 2022-2027 (%)
    • Exhibit 59: Data Table on Heparin – Year-over-year growth 2022-2027 (%)
  • 7.6 Vitamin K antagonists – Market size and forecast 2022-2027 
    • Exhibit 60: Chart on Vitamin K antagonists – Market size and forecast 2022-2027 ($ million)
    • Exhibit 61: Data Table on Vitamin K antagonists – Market size and forecast 2022-2027 ($ million)
    • Exhibit 62: Chart on Vitamin K antagonists – Year-over-year growth 2022-2027 (%)
    • Exhibit 63: Data Table on Vitamin K antagonists – Year-over-year growth 2022-2027 (%)
  • 7.7 Market opportunity by Type 
    • Exhibit 64: Market opportunity by Type ($ million)
    • Exhibit 65: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview 
    • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation 
    • Exhibit 67: Chart on Market share by geography 2022-2027 (%)
    • Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison 
    • Exhibit 69: Chart on Geographic comparison
    • Exhibit 70: Data Table on Geographic comparison
  • 9.3 North America – Market size and forecast 2022-2027
    • Exhibit 71: Chart on North America – Market size and forecast 2022-2027 ($ million)
    • Exhibit 72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
    • Exhibit 73: Chart on North America – Year-over-year growth 2022-2027 (%)
    • Exhibit 74: Data Table on North America – Year-over-year growth 2022-2027 (%)
  • 9.4 Europe – Market size and forecast 2022-2027
    • Exhibit 75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
    • Exhibit 76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
    • Exhibit 77: Chart on Europe – Year-over-year growth 2022-2027 (%)
    • Exhibit 78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
  • 9.5 Asia – Market size and forecast 2022-2027
    • Exhibit 79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
    • Exhibit 80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
    • Exhibit 81: Chart on Asia – Year-over-year growth 2022-2027 (%)
    • Exhibit 82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) – Market size and forecast 2022-2027 
    • Exhibit 83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
    • Exhibit 84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
    • Exhibit 85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
    • Exhibit 86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
  • 9.7 US – Market size and forecast 2022-2027
    • Exhibit 87: Chart on US – Market size and forecast 2022-2027 ($ million)
    • Exhibit 88: Data Table on US – Market size and forecast 2022-2027 ($ million)
    • Exhibit 89: Chart on US – Year-over-year growth 2022-2027 (%)
    • Exhibit 90: Data Table on US – Year-over-year growth 2022-2027 (%)
  • 9.8 Germany – Market size and forecast 2022-2027
    • Exhibit 91: Chart on Germany – Market size and forecast 2022-2027 ($ million)
    • Exhibit 92: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
    • Exhibit 93: Chart on Germany – Year-over-year growth 2022-2027 (%)
    • Exhibit 94: Data Table on Germany – Year-over-year growth 2022-2027 (%)
  • 9.9 UK – Market size and forecast 2022-2027
    • Exhibit 95: Chart on UK – Market size and forecast 2022-2027 ($ million)
    • Exhibit 96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
    • Exhibit 97: Chart on UK – Year-over-year growth 2022-2027 (%)
    • Exhibit 98: Data Table on UK – Year-over-year growth 2022-2027 (%)
  • 9.10 Japan – Market size and forecast 2022-2027
    • Exhibit 99: Chart on Japan – Market size and forecast 2022-2027 ($ million)
    • Exhibit 100: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
    • Exhibit 101: Chart on Japan – Year-over-year growth 2022-2027 (%)
    • Exhibit 102: Data Table on Japan – Year-over-year growth 2022-2027 (%)
  • 9.11 Canada – Market size and forecast 2022-2027
    • Exhibit 103: Chart on Canada – Market size and forecast 2022-2027 ($ million)
    • Exhibit 104: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
    • Exhibit 105: Chart on Canada – Year-over-year growth 2022-2027 (%)
    • Exhibit 106: Data Table on Canada – Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography 
    • Exhibit 107: Market opportunity by geography ($ million)
    • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.3 Impact of drivers and challenges 
    • Exhibit 109: Impact of drivers and challenges in 2022 and 2027

11 Vendor Landscape

  • 11.2 Vendor landscape 
    • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption 
    • Exhibit 111: Overview on factors of disruption
  • 11.4 Industry risks 
    • Exhibit 112: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered 
    • Exhibit 113: Vendors covered
  • 12.2 Market positioning of vendors 
    • Exhibit 114: Matrix on vendor position and classification
  • 12.3 Abbott Laboratories 
    • Exhibit 115: Abbott Laboratories – Overview
    • Exhibit 116: Abbott Laboratories – Business segments
    • Exhibit 117: Abbott Laboratories – Key news
    • Exhibit 118: Abbott Laboratories – Key offerings
    • Exhibit 119: Abbott Laboratories – Segment focus
  • 12.4 Aspen Pharmacare Holdings Ltd 
    • Exhibit 120: Aspen Pharmacare Holdings Ltd – Overview
    • Exhibit 121: Aspen Pharmacare Holdings Ltd – Business segments
    • Exhibit 122: Aspen Pharmacare Holdings Ltd – Key offerings
    • Exhibit 123: Aspen Pharmacare Holdings Ltd – Segment focus
  • 12.5 AstraZeneca PLC 
    • Exhibit 124: AstraZeneca PLC – Overview
    • Exhibit 125: AstraZeneca PLC – Product / Service
    • Exhibit 126: AstraZeneca PLC – Key news
    • Exhibit 127: AstraZeneca PLC – Key offerings
  • 12.6 Bayer AG 
    • Exhibit 128: Bayer AG – Overview
    • Exhibit 129: Bayer AG – Business segments
    • Exhibit 130: Bayer AG – Key news
    • Exhibit 131: Bayer AG – Key offerings
    • Exhibit 132: Bayer AG – Segment focus
  • 12.7 Boehringer Ingelheim International GmbH
    • Exhibit 133: Boehringer Ingelheim International GmbH – Overview
    • Exhibit 134: Boehringer Ingelheim International GmbH – Business segments
    • Exhibit 135: Boehringer Ingelheim International GmbH – Key news
    • Exhibit 136: Boehringer Ingelheim International GmbH – Key offerings
    • Exhibit 137: Boehringer Ingelheim International GmbH – Segment focus
  • 12.8 Bristol Myers Squibb Co. 
    • Exhibit 138: Bristol Myers Squibb Co. – Overview
    • Exhibit 139: Bristol Myers Squibb Co. – Product / Service
    • Exhibit 140: Bristol Myers Squibb Co. – Key news
    • Exhibit 141: Bristol Myers Squibb Co. – Key offerings
  • 12.9 Daiichi Sankyo Co. Ltd. 
    • Exhibit 142: Daiichi Sankyo Co. Ltd. – Overview
    • Exhibit 143: Daiichi Sankyo Co. Ltd. – Product / Service
    • Exhibit 144: Daiichi Sankyo Co. Ltd. – Key news
    • Exhibit 145: Daiichi Sankyo Co. Ltd. – Key offerings
  • 12.10 Dr Reddys Laboratories Ltd. 
    • Exhibit 146: Dr Reddys Laboratories Ltd. – Overview
    • Exhibit 147: Dr Reddys Laboratories Ltd. – Business segments
    • Exhibit 148: Dr Reddys Laboratories Ltd. – Key offerings
    • Exhibit 149: Dr Reddys Laboratories Ltd. – Segment focus
  • 12.11 GlaxoSmithKline Plc 
    • Exhibit 150: GlaxoSmithKline Plc – Overview
    • Exhibit 151: GlaxoSmithKline Plc – Business segments
    • Exhibit 152: GlaxoSmithKline Plc – Key news
    • Exhibit 153: GlaxoSmithKline Plc – Key offerings
    • Exhibit 154: GlaxoSmithKline Plc – Segment focus
  • 12.12 Johnson and Johnson Services Inc.
    • Exhibit 155: Johnson and Johnson Services Inc. – Overview
    • Exhibit 156: Johnson and Johnson Services Inc. – Business segments
    • Exhibit 157: Johnson and Johnson Services Inc. – Key news
    • Exhibit 158: Johnson and Johnson Services Inc. – Key offerings
    • Exhibit 159: Johnson and Johnson Services Inc. – Segment focus
  • 12.13 LEO Pharma AS 
    • Exhibit 160: LEO Pharma AS – Overview
    • Exhibit 161: LEO Pharma AS – Business segments
    • Exhibit 162: LEO Pharma AS – Key offerings
    • Exhibit 163: LEO Pharma AS – Segment focus
  • 12.14 Novartis AG 
    • Exhibit 164: Novartis AG – Overview
    • Exhibit 165: Novartis AG – Business segments
    • Exhibit 166: Novartis AG – Key offerings
    • Exhibit 167: Novartis AG – Segment focus
  • 12.15 Pfizer Inc. 
    • Exhibit 168: Pfizer Inc. – Overview
    • Exhibit 169: Pfizer Inc. – Product / Service
    • Exhibit 170: Pfizer Inc. – Key news
    • Exhibit 171: Pfizer Inc. – Key offerings
  • 12.16 Sanofi SA 
    • Exhibit 172: Sanofi SA – Overview
    • Exhibit 173: Sanofi SA – Business segments
    • Exhibit 174: Sanofi SA – Key news
    • Exhibit 175: Sanofi SA – Key offerings
    • Exhibit 176: Sanofi SA – Segment focus
  • 12.17 Teva Pharmaceutical Industries Ltd.
    • Exhibit 177: Teva Pharmaceutical Industries Ltd. – Overview
    • Exhibit 178: Teva Pharmaceutical Industries Ltd. – Business segments
    • Exhibit 179: Teva Pharmaceutical Industries Ltd. – Key news
    • Exhibit 180: Teva Pharmaceutical Industries Ltd. – Key offerings
    • Exhibit 181: Teva Pharmaceutical Industries Ltd. – Segment focus

13 Appendix

  • 13.1 Scope of the report 
  • 13.2 Inclusions and exclusions checklist
    • Exhibit 182: Inclusions checklist
    • Exhibit 183: Exclusions checklist
  • 13.3 Currency conversion rates for US$ 
    • Exhibit 184: Currency conversion rates for US$
  • 13.4 Research methodology 
    • Exhibit 185: Research methodology
    • Exhibit 186: Validation techniques employed for market sizing
    • Exhibit 187: Information sources
  • 13.5 List of abbreviations 
    • Exhibit 188: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending